Publications by authors named "Lucille Donatacci"

Claim this Profile
E
Efficacy and safety of 48 weeks of enfuvirtide 180 mg once-daily dosing versus 90 mg twice-daily dosing in HIV-infected patients.
David Wright, Allen Rodriguez, Eliot Godofsky, Sharon Walmsley, Emily Labriola-Tompkins, Lucille Donatacci

HIV Clin Trials· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adherence to enfuvirtide and its impact on treatment efficacy.
Jürgen Rockstroh, Edwin Dejesus, Lucille Donatacci, Cynthia Wat, Anne Bertasso

AIDS Res Hum Retroviruses· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TORO: ninety-six-week virologic and immunologic response and safety evaluation of enfuvirtide with an optimized background of antiretrovirals.
Jacques Reynes, Keikawus Arastéh, Bonaventura Clotet, Calvin Cohen, David A Cooper, Lucille Donatacci

AIDS Patient Care STDS· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Durable efficacy of enfuvirtide over 48 weeks in heavily treatment-experienced HIV-1-infected patients in the T-20 versus optimized background regimen only 1 and 2 clinical trials.
Mark Nelson, Keikawus Arastéh, Bonaventura Clotet, David A Cooper, Keith Henry, Lucille Donatacci

J Acquir Immune Defic Syndr· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America.
Jacob P Lalezari, Keith Henry, Mary O'Hearn, Julio S G Montaner, Peter J Piliero, Lucille Donatacci

N Engl J Med· May 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis